Baliopharm Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • 2ndary - Private

Baliopharm General Information

Description

Developer of antibody-derived therapeutics designed to treat chronic liver diseases, immune-mediated inflammatory diseases, and cancer. The company offers monoclonal antibodies, monovalent formats, and bispecifics, enabling healthcare organizations to address acute and chronic conditions with increased target selectivity and enhanced safety profiles.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • Pfeffingerstrasse 19
  • Reinach
  • 4153 Basel
  • Switzerland
+41 061
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Corporate Office
  • Pfeffingerstrasse 19
  • Reinach
  • 4153 Basel
  • Switzerland
+41 061

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Baliopharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private Completed Generating Revenue
2. Later Stage VC 01-Jan-2021 Completed Generating Revenue
1. Merger/Acquisition 10-Apr-2018 Completed Generating Revenue
To view Baliopharm’s complete valuation and funding history, request access »

Baliopharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antibody-derived therapeutics designed to treat chronic liver diseases, immune-mediated inflammatory diseas
Drug Discovery
Basel, Switzerland

Cambridge, MA

Rixensart, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Baliopharm Competitors (49)

One of Baliopharm’s 49 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Formerly VC-backed Cambridge, MA
CuraVac Formerly Accelerator/Incubator backed Rixensart, Belgium
Agomab Therapeutics Formerly VC-backed Antwerp, Belgium
Verona Pharma Corporate Backed or Acquired London, United Kingdom
Xenikos Venture Capital-Backed Nijmegen, Netherlands
You’re viewing 5 of 49 competitors. Get the full list »

Baliopharm Patents

Baliopharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018371232-A1 Anti-hutnfr1 therapy of nonalcoholic steatohepatitis Active 27-Nov-2017
AU-2018371232-B2 Anti-hutnfr1 therapy of nonalcoholic steatohepatitis Active 27-Nov-2017
AU-2018371232-B9 Anti-hutnfr1 therapy of nonalcoholic steatohepatitis Active 27-Nov-2017
CA-3081493-A1 Anti-hutnfr1 therapy of nonalcoholic steatohepatitis Pending 27-Nov-2017
EP-3717068-A1 Anti-hutnfr1 therapy of nonalcoholic steatohepatitis Pending 27-Nov-2017 A61P1/16
To view Baliopharm’s complete patent history, request access »

Baliopharm Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Xlife Sciences Venture Capital Minority
To view Baliopharm’s complete investors history, request access »

Baliopharm Investments (1)

Baliopharm’s most recent deal was a Seed Round with 3Z for . The deal was made on 05-Jul-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
3Z 05-Jul-2016 Seed Round Drug Discovery
To view Baliopharm’s complete investments history, request access »

Baliopharm FAQs

  • When was Baliopharm founded?

    Baliopharm was founded in 2006.

  • Where is Baliopharm headquartered?

    Baliopharm is headquartered in Basel, Switzerland.

  • What industry is Baliopharm in?

    Baliopharm’s primary industry is Drug Discovery.

  • Is Baliopharm a private or public company?

    Baliopharm is a Private company.

  • What is Baliopharm’s current revenue?

    The current revenue for Baliopharm is .

  • Who are Baliopharm’s investors?

    Xlife Sciences has invested in Baliopharm.

  • Who are Baliopharm’s competitors?

    AnTolRx, CuraVac, Agomab Therapeutics, Verona Pharma, and Xenikos are some of the 49 competitors of Baliopharm.

  • Who acquired Baliopharm?

    Baliopharm was acquired by Cellaion.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process